Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
about
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databasesBiologics registers in RA: methodological aspects, current role and future applications.[Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry.Etanercept protects rat cardiomyocytes against hypertrophy by regulating inflammatory cytokines secretion and cell apoptosisDrug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registryNovel Adherence Measures for Infusible Therapeutic Agents Indicated for Rheumatoid ArthritisCirculating complexes between tumour necrosis factor-alpha and etanercept predict long-term efficacy of etanercept in juvenile idiopathic arthritis.A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy - results from a Swedish cohort study.Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice.Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.Long-Term Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis: An Observational Analysis from the Corrona Rheumatoid Arthritis Registry.Medication Persistence of Disease-Modifying Antirheumatic Drugs and Anti-Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil.Drug survival on tumour necrosis factor inhibitors in patients with rheumatoid arthritis in Finland.The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range.Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis.Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.Does disease activity at the start of biologic therapy influence health care costs in patients with RA?The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis.Effectiveness and survival-on-drug of certolizumab pegol in rheumatoid arthritis in clinical practice: results from the national Swedish register.Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment.A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab.Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.Drug survival and the associated predictors in South Korean patients with rheumatoid arthritis receiving tacrolimus.Improved safety of biologic therapy for rheumatoid arthritis over the 8-year period since implementation in Japan: long-term results from a multicenter observational cohort study.Reasons for Discontinuation and Adverse Effects of TNFα Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis.Infliximab is equivalently suppressing oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.Crude leaf extracts of Piperaceae species downmodulate inflammatory responses by human monocytes.
P2860
Q26778600-C6620206-DD1D-4499-9137-EF79182C19D9Q30234303-204F0CB0-72F6-408A-B7F1-3D7EA28703AFQ30962462-6C7C4321-FCCC-4A76-B5BE-158FA78A9662Q31021097-1FC1A7A7-E48E-458D-856C-2A90C94F1545Q33821362-811423BF-5927-4942-B98C-C385B0F9EC99Q34208252-504F3C41-D10A-4375-841C-40034E1DA7FCQ36216285-586921D5-9BAF-4DF4-8628-5F3C4C1D0699Q36267465-B6036AA4-03AD-48AC-A2CF-F1D1A8465267Q36480601-E56F4685-FC8C-4A4E-B94E-4B3F9CA2A0D4Q37343947-AD719A2A-3DC5-47A7-9BEE-4279FC647D34Q37470261-0049B3D0-BC69-43C9-831E-D19885D04793Q37471597-FED25F41-3835-4A17-A66E-4519B839B9D8Q38357886-8344AE14-E930-4F38-94D4-867007F647FAQ38404761-99B28381-68E8-4BFF-B47E-D557A7FED4A0Q38406712-0F2AF965-94F1-4241-8A22-7A652649CB31Q38608695-C53D952E-6956-403F-90F2-B78AB89FEF68Q38915704-E21FE0B1-6C95-4833-849C-420B7ACDF672Q39033025-55326719-0F8D-4E7D-9AF4-8907F91C2B4CQ40206740-7CC5F463-DD62-4D4B-AB05-31DCB9851196Q40314992-87D0EB8D-2E67-4EDD-B5BB-E0D70D7E410BQ40548376-3349BB6C-EDF6-4F60-B877-C043C485D9A5Q40735887-6414197E-9F30-4C54-A226-E31C788BC278Q41183360-7C96AD7F-9BB3-4F1E-B6A8-BAFE5B7DD6AEQ41359123-476FF6F6-1631-4E53-AC26-2408E7569A77Q41433650-C7DD9BBC-81F1-4687-B11C-63098D393D6DQ41662059-BA982B04-0B38-4582-B03D-2014DC01B7A4Q47107623-8B165551-05B1-433E-B0D1-4CAE69DC6EEEQ47367453-690699A6-94AE-4047-B496-4DACC14A3AE4Q47441501-8B5F1EC7-59D3-4A0C-9D96-E12DEEB7F434Q47633961-68EE182A-4894-40D3-A191-914C8FAD1C20Q47810854-6A33F0D3-6120-450C-8001-A78F5C205FD6Q47983950-16D8DF20-007A-4710-B1CE-0C16F4FBEBC0Q48026614-D6878D4C-A02A-4AED-B28C-B80BB0DF95C3Q48122799-A5B77C37-5ADE-45EE-8171-D7C59B623201Q49370571-FBEE206D-78DF-4E2D-942E-CE8227136418Q50262782-5B9DFA40-31DC-4389-B1D7-1DA11BA0BFACQ51026740-A5C075AA-3537-4889-BBC0-005ED0E27757Q51364675-39790B2B-C90C-47D0-A371-887A7B182B72Q52653996-B94258CA-1083-43FA-B809-D9E8202C6F72Q55433516-F3F5D608-7079-41C8-9E73-837A06EC0BEB
P2860
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Drug survival on TNF inhibitor ...... ab, etanercept and infliximab.
@en
type
label
Drug survival on TNF inhibitor ...... ab, etanercept and infliximab.
@en
prefLabel
Drug survival on TNF inhibitor ...... ab, etanercept and infliximab.
@en
P2093
P2860
P50
P1476
Drug survival on TNF inhibitor ...... ab, etanercept and infliximab.
@en
P2093
ARTIS Study Group
J K Eriksson
L E Kristensen
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-204128
P407
P577
2013-11-27T00:00:00Z